Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 265.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 114,965 shares of the specialty pharmaceutical company's stock after buying an additional 83,548 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.35% of Collegium Pharmaceutical worth $4,442,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in COLL. Emerald Advisers LLC raised its holdings in Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company's stock worth $31,967,000 after acquiring an additional 177,129 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Collegium Pharmaceutical by 4.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company's stock worth $908,000 after acquiring an additional 983 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Collegium Pharmaceutical by 24.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company's stock valued at $25,591,000 after buying an additional 131,835 shares during the period. Farther Finance Advisors LLC grew its position in shares of Collegium Pharmaceutical by 5,408.5% in the third quarter. Farther Finance Advisors LLC now owns 11,678 shares of the specialty pharmaceutical company's stock valued at $451,000 after purchasing an additional 11,466 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Collegium Pharmaceutical by 61.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock valued at $239,000 after acquiring an additional 2,352 shares during the last quarter.

Analysts Set New Price Targets

COLL has been the subject of several recent research reports. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright increased their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. Finally, Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

Collegium Pharmaceutical Trading Down 7.3 %

NASDAQ COLL traded down $2.55 during trading hours on Friday, hitting $32.16. 1,018,848 shares of the company were exchanged, compared to its average volume of 296,884. The stock has a 50-day moving average price of $37.07 and a 200 day moving average price of $35.21. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a 52 week low of $23.44 and a 52 week high of $42.29. The stock has a market cap of $1.04 billion, a PE ratio of 12.47 and a beta of 0.95.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million for the quarter, compared to analysts' expectations of $143.94 million. During the same quarter in the prior year, the company earned $1.13 earnings per share. The business's quarterly revenue was up 7.2% on a year-over-year basis. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.81 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company's stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company's stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.